Monograph Details
|
|
Pain & Pyrexia
> Nonnarcotic analgesics
|
|
NAPROSYN SUSPENSION |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
NSAID (arylacetic acid deriv.). |
| Generic Name |
|
Naproxen 125mg/5mL; pineapple-orange flavor. |
| Also |
• EC-NAPROSYN
• NAPROSYN
|
| Indications |
|
Mild to moderate pain. |
| Children |
|
<2yrs: not recommended. ≥2yrs: use susp forms of naproxen. |
| Adults |
|
Initially 500mg, then 500mg every 12 hrs or 250mg every 6–8 hrs; max 1.25g (first day), then max 1g/day. |
| Contraindications |
|
Aspirin allergy. Coronary artery bypass graft surgery. |
| Precautions |
|
Advanced renal disease: not recommended. Active peptic ulcer. History of GI or inflammatory bowel disease. Impaired renal or hepatic function. Heart failure. Edema. Hypertension. Preexisting asthma. Bleeding disorders. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended. |
| Interactions |
|
Avoid concomitant aspirin. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas). Monitor oral anticoagulants. Increased risk of GI bleeding with oral corticosteroids, SSRIs, smoking, alcohol. May antagonize diuretics, β-blockers, other antihypertensives. Increased renal toxicity with ACE inhibitors. Methotrexate excretion reduced. Increases serum lithium levels. Probenecid increases plasma levels and delays elimination. Concomitant H2 blockers, sucralfate, intensive antacid therapy: use immediate-release forms of naproxen. Cholestyramine may delay absorption. |
| Adverse Reactions |
|
GI bleeding, peptic ulcer, constipation, heartburn, abdominal pain, nausea, headache, dizziness, drowsiness, pruritus, rash (discontinue if occurs), tinnitus, edema, nephritis, nephrotic syndrome, jaundice, hepatitis. See literature re: risk of cardiovascular events. |
| How Supplied |
Tabs—100
Susp—pt |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
